Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib‐refractory ALK‐positive NSCLC from a phase II study

Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib‐refractory ALK‐positive NSCLC from a phase II study

Abstract Background The initial phase II stuty (NCT03215693) demonstrated that ensartinib has shown clinical activity in patients with advanced crizotinib‐refractory, anaplastic lymphoma kinase (ALK)‐positive non‐small cell lung cancer (NSCLC). Herein, we reported the updated data on overall surviva...

Full description

Bibliographic Details
Main Authors: Jing Zheng, Tao Wang, Yunpeng Yang, Jie Huang, Jifeng Feng, Wu Zhuang, Jianhua Chen, Jun Zhao, Wei Zhong, Yanqiu Zhao, Yiping Zhang, Yong Song, Yi Hu, Zhuang Yu, Youling Gong, Yuan Chen, Feng Ye, Shucai Zhang, Lejie Cao, Yun Fan, Gang Wu, Yubiao Guo, Chengzhi Zhou, Kewei Ma, Jian Fang, Weineng Feng, Yunpeng Liu, Zhendong Zheng, Gaofeng Li, Huijie Wang, Shundong Cang, Ning Wu, Wei Song, Xiaoqing Liu, Shijun Zhao, Lieming Ding, Giovanni Selvaggi, Yang Wang, Shanshan Xiao, Qian Wang, Zhilin Shen, Jianya Zhou, Jianying Zhou, Li Zhang
Format: Article
Language:English
Published: Wiley 2024-04-01
Series:Cancer Communications
Subjects:
anaplastic lymphoma kinase
ctDNA
ensartinib
non‐small cell lung cancer
overall survival
Online Access:https://doi.org/10.1002/cac2.12524

Internet

https://doi.org/10.1002/cac2.12524

Similar Items